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COL6A3 expression in adipose 
tissue cells is associated with levels 
of the homeobox transcription 
factor PRRX1
Simon N. Dankel1,2*, Elise Grytten1,2, Jan‑Inge Bjune1,2, Hans Jørgen Nielsen3, 
Arne Dietrich4, Matthias Blüher5, Jørn V. Sagen1,2 & Gunnar Mellgren1,2*
Fibrillar collagen COL6α3 in adipose tissue has been associated with obesity, inflammation, insulin 
resistance and cancer. We here aimed to identify novel transcriptional regulators of COL6A3 
expression. Based on a transcriptome dataset of adipose tissue, we identified strong correlations 
for 56 genes with COL6A3 mRNA, including targets of TGF‑β/SMAD signaling. Among the identified 
candidates, the homeobox transcription factor PRRX1 showed a particularly striking co‑expression 
with COL6A3, validated across several different cohorts, including patients with extreme obesity, 
insulin sensitive and resistant obesity (subcutaneous and omental), after profound fat loss 
(subcutaneous), and lean controls (subcutaneous). In human and mouse adipose cells, PRRX1 
knockdown reduced COL6A3 mRNA and PRRX1 overexpression transactivated a reporter construct 
with the endogenous human COL6A3 promoter. Stable PRRX1 overexpression in 3T3‑L1 cells 
induced Col6a3 mRNA threefold specifically after adipogenic induction, whereas TGF‑β1 treatment 
upregulated Col6a3 mRNA also in the preadipocyte state. Interestingly, pro‑inflammatory stimulus 
(i.e., TNF‑α treatment) decreased PRRX1‑mediated Col6a3 transactivation and mRNA expression, 
supporting a role for this mechanism in the regulation of adipose tissue inflammation. In conclusion, 
we identified the homeobox factor PRRX1 as a novel transcriptional regulator associated with COL6A3 
expression, providing new insight into the regulatory mechanisms of altered adipose tissue function in 
obesity and insulin resistance.
Altered adipose tissue function during chronic energy surplus mediates systemic insulin resistance and disease 
 pathogenesis1. The pathogenic potential of adipose tissue partly involves hypertrophied single adipocytes due to 
insufficient regeneration of new adipocytes, and restrained tissue expandability resulting from increased rigidity 
of the extracellular matrix (ECM)1. Pro-inflammatory macrophages can impair preadipocyte differentiation into 
mature adipocytes and promote a pro-fibrotic preadipocyte phenotype, in part involving transforming growth 
factor β (TGF-β) and tumor necrosis factor α (TNF-α)  signaling2,3. In turn, both impaired adipogenesis and 
increased collagen deposition may disrupt the normal lipid storage capacity of adipose tissue during energy 
surplus, and lead to glucotoxicity and  lipotoxicity4,5.
Collagen constitutes a microfibrillar network composed of several different types of collagen fibrils, including 
type I and type VI alpha 1–3 (encoded by the genes COL1 and COL6A1-3, respectively). Several studies have 
implicated COL6 in altered adipose tissue function in obesity and insulin resistance. For instance, Col6 knock-
out mice were protected from diet-induced metabolic dysregulation despite adipocyte  hypertrophy6, at least 
partly dependent on pro-fibrotic and pro-inflammatory effects of a Col6α3-derived signaling peptide called 
endotrophin acting on  adipocytes7,8. Adipocyte-derived endotrophin may also promote breast cancer via ECM 
 interactions9,10, and circulating Col6α3 may serve as a prognostic marker for  cancer11,12. In human adipose tissue, 
consistent with rodent models, up-regulation of COL6A3 associates positively with obesity-related inflammation, 
insulin resistance and metabolic  dysregulation13,14. COL6α3 may partly promote insulin resistance by restricting 
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adipogenesis. We have observed increased COL6A3 expression in small compared to large adipocytes, and after 
knockdown of the insulin sensitizing transcription factor peroxisome proliferator activator gamma (PPARγ)15. 
Others also found that knockdown of COL6A3 in primary human adipocytes suppressed macrophage chemoat-
tractant protein MCP1, supporting pro-inflammatory effects of COL6α316.
Yet, seemingly contradictory to these compelling data, studies have reported decreased adipose COL6A3 
mRNA expression in extreme obesity in the context of high inflammatory gene expression, and increased 
COL6A3 mRNA after profound fat loss in the same  people17, as well as increased COL6A3 mRNA after a very 
low-calorie  diet18. These data indicate a complex regulation of COL6A3 in adipose tissue dependent on specific 
metabolic states and transcriptional context. We here sought to improve our understanding of adipose COL6A3 
regulation, which could potentially identify novel therapeutic targets for modulating adipose tissue function. 
Based on a systematic co-expression analysis for COL6A3, together with co-expression patterns in additional 
cohorts, knockdown experiments and functional transactivation assays, we here discovered paired related home-
obox 1 (PRRX1) as a novel positive regulator of COL6A3 expression.
Results
Co‑expression analysis reveals correlation of COL6A3 and PRRX1 mRNA levels. Co-expression 
analysis may reveal transcriptional regulators of a target gene of interest. Thus, to probe for potential transcrip-
tional regulators of COL6A3, we correlated COL6A3 mRNA with other mRNA transcripts in our previously 
published global transcriptome analysis of subcutaneous adipose tissue, which included 16 people with obesity 
before and after profound fat loss as well as 13 lean  people17 (Cohort 1, Table  1). This co-expression analy-
sis revealed 56 unique curated genes whose mRNA levels correlated strongly with COL6A3 mRNA (Pearson’s 
r > 0.75), thereof 4 inversely correlated genes (Table S2). Among the 52 positively co-expressed genes were sev-
eral other genes encoding collagens (COL1A1, COL1A2, COL3A1 and COL5A1).
To gain insight into the transcriptional regulation of the set of 56 COL6A3-co-expressed genes as a whole, we 
interrogated a database of known transcription factor (TF)-target gene interactions (TFactS)19. The COL6A3-
associated gene set showed a particularly strong enrichment for targets of SMAD3 (4 genes), SMAD7 (4 genes), 
TFAP2A (4 genes) and SPI1 (3 genes), including COL6A3 and other collagen genes identified as targets of 
SMAD3 and SMAD7 (Tables S3-4). COL1A1, COL1A2, COL3A1 and COL5A1 were also predicted targets of 
several other TFs (Table S4). SMAD TFs mediate signaling by the TGF-β superfamily of ligands, including bone 
morphogenic proteins (BMPs), growth and differentiation factors (GDFs) and TGF-βs, which play a critical role 
in development and homeostasis from embryogenesis through  adulthood20. TGF-β signaling has been shown 
to prevent downregulation of collagen genes in fibroblasts and to impair  adipogenesis21,22. However, none of the 
genes encoding these TFs showed co-expression with COL6A3 in our dataset. To prioritize potentially novel TFs 
that may contribute importantly to the regulation of COL6A3 expression, we used a curated list of transcription 
 factors23 and identified four TF-encoding genes among the 56 top COL6A3 co-expressed genes (PRRX1, KLF12, 
ZNF789 and ZFHX4). Among these, PRRX1 showed the strongest correlation (Pearson’s r = 0.881) and highest 
expression level in the adipose tissue (Fig. 1A). The strong positive correlation for PRRX1 and COL6A3 was 
evident within each subgroup (subcutaneous fat in the lean, obese and obese after fat loss, and omental fat in 
the obese) (Figure S1A), and also for the change in PRRX1 mRNA in relation to the change in COL6A3 mRNA 
after profound fat loss (Fig. 1B). These data revealed a striking correlation between PRRX1 and COL6A3 mRNA 
levels in adipose tissue.
By qPCR we further sought to validate the co-expression of PRRX1 and COL6A3 in adipose samples from 
additional cohorts, including different adipose depots and isolated human adipocytes and stromal vascular 
Table 1.  Clinical characteristics of subjects included in the study. BMI, body-mass index (kg/m2); hASCs, 
human adipose stromal cells; IRO, insulin resistant obese; ISO, insulin sensitive obese; OM, omental 
adipose tissue; Pre, before bariatric surgery; Post, one year after bariatric surgery/after profound fat loss; SC, 
subcutaneous adipose tissue; SVF, stromal vascular fraction.
Men/women Age (years) BMI (kg/m2) Specific analyses Figure
Cohort 1
Pre 4/12 39.3 ± 10.9 53.3 ± 4.3 Whole SC/OM 1A-B, S1A
Post 4/12 40.3 ± 10.9 33.1 ± 5.0
Lean 7/6 44.0 ± 17.5 23.0 ± 2.5
Cohort 2
ISO 10/20 44.6 ± 1.9 45.1 ± 1.3 Whole SC/OM, euglycemic hyperinsulinemic clamp 1C-D
IRO 10/20 44.9 ± 2.1 45.2 ± 1.3
Cohort 3
Obese 4/8 43.1 ± 10.4 43.7 ± 5.4 Isolated mature SC/OM adipocytes, SVF 2, S1B
Lean 5/7 43.5 ± 11.6 22.8 ± 2.1
hASCs
0/4 44.5 ± 6.6 31.2 ± 5.2 Cultured and differentiated SC SVF S2A, 3
1/3 39.0 ± 13.8 24.0 ± 1.4 siRNA knockdown experiments
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fraction (SVF). We previously reported increased COL6A3 mRNA in insulin resistant compared to insulin 
sensitive obese  patients15. These patients were otherwise healthy and matched for age, sex, BMI and total body 
 fat24. Similar to COL6A3 in these patients (Cohort 2, Table 1), PRRX1 showed 2–threefold higher expression in 
both subcutaneous and omental adipose tissue in the insulin resistant compared to the insulin sensitive patients 
(Fig. 1C,D). Consistent with the initial cohort, each of the depots showed a strong positive correlation between 
PRRX1 and COL6A3 mRNA (Fig. 1D).
Comparing adipocytes and SVF in another cohort (Cohort 3, Table 1), the two genes showed a highly similar 
expression pattern across lean and obese subcutaneous and obese omental samples, with highest expression in 
subcutaneous SVF in obesity (Fig. 2A). This corresponded to strong positive correlations in both adipocytes and 
SVF (Fig. 2B). Also the omental samples (available from the 12 patients with obesity) showed positive correlations 
of PRRX1 and COL6A3 mRNA (SVF: p = 8.66E-5, r = 0.894; adipocytes: p = 0.263, r = 0.335, data now shown). 
The microarray analysis showed considerably lower expression levels for KLF12, ZNF789 and ZFHX4, with 
similar expression in adipocytes and SVF, in contrast to COL6A3 and PRRX1 (Figure S1B). Together, these data 
show a consistent co-expression of PRRX1 and COL6A3 in adipose tissue across different phenotypic contexts 
and nutritional states, suggesting that PRRX1 might contribute to the transcriptional regulation of COL6A3.
We and others previously identified PRRX1 as a suppressor of  adipogenesis25,26. We here assessed the expres-
sion profiles of PRRX1 and COL6A3 during adipogenic differentiation. In primary human adipose cultures, 
neither gene showed a notable change in expression throughout differentiation (Figure S2A). Increased expres-
sion of PPARG variant 2 and morphological analysis confirmed that the cells differentiated into adipocytes 
(Figure S2A). In 3T3-L1 mouse adipocytes, Col6a3 mRNA showed fluctuating expression although there was 
notable variation across experiments (Figure S2B). On the other hand, Prrx1 mRNA consistently showed a 
marked decrease throughout differentiation. Both genes showed relatively stable expression in undifferentiated 
cells grown in parallel with differentiated cells (Figure S2B). Increased Pparg variant 2 expression confirmed 




































11.5 12 12.5 13 13.5









11.5 12 12.5 13 13.5
Obese after fat loss (SC)Obese (SC)Lean (SC)

























































































COL6A3 mRNA ratio (log2)




p < 0.001 p < 0.001 p < 0.001 p < 0.001
***
***
Figure 1.  PRRX1 and COL6A3 mRNA correlate in human adipose tissue. (A) Adipose tissue biopsies were 
obtained from extremely obese subjects (subcutaneous n = 16, omental n = 12). Subcutaneous adipose tissue was 
also obtained from the same subjects after profound fat loss (one year after bariatric surgery, n = 16), and from 
healthy non-obese subjects (n = 14). Gene expression was measured by Illumina microarrays, log2-transformed 
expression values are shown. Pearson correlations (r) of COL6A3 mRNA and the mRNA expression of identified 
potential transcriptional regulators of COL6A3 are shown. (B) Correlation between the change of PRRX1 
mRNA and change of COL6A3 mRNA after fat loss in 16 pairs of subcutaneous adipose tissue samples collected 
before and one year after bariatric surgery. (C) PRRX1 mRNA expression in subcutaneous and omental adipose 
tissue in 30 morbidly obese insulin sensitive and 30 BMI-matched morbidly obese insulin resistant people, 
measured by qPCR and calculated relative to HPRT1 mRNA. Insulin sensitivity was measured by euglycemic 
hyperinsulinemic clamp. (D) Correlation of relative PRRX1 and COL6A3 mRNA across the BMI-matched 
morbidly obese insulin sensitive and resistant groups, for subcutaneous and omental adipose tissue, respectively. 
SC, subcutaneous; OM, omental. ***p value < 0.001.
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PRRX1 transactivates COL6A3. To assess whether PRRX1 may be a novel transcriptional regulator of 
adipose COL6A3 expression, and not merely co-expressed, we next silenced PRRX1 in human adipose cells and 
measured endogenous COL6A3 mRNA expression. When differentiating SGBS or primary human preadipo-
cytes for 3–4 days, we found that knock-down of PRRX1 mRNA led to 20–30% reduction in COL6A3 mRNA 
(Fig. 3A).
We previously observed that knockdown of PPARG increased COL6A3 mRNA in differentiating primary 
human adipocytes, indicating that PPARγ is a negative regulator of COL6A3  mRNA15. Furthermore, in a sepa-
rate study we demonstrated that PRRX1 inhibits PPARG mRNA expression in the early phase of adipogenic 
 differentiation25. We here tested if PRRX1 knockdown would counteract the upregulation of COL6A3 mRNA 
after PPARG knockdown in early adipogenesis. As hypothesized, PRRX1 silencing significantly blunted the 
upregulation of COL6A3 mRNA caused by PPARG knockdown (Fig. 3B). Taken together, these data indicate that 
increased expression of COL6A3 in these cells at least partly depends on the simultaneous presence of PRRX1 
and reduction in PPARγ.
We consequently tested the transcriptional regulation of COL6A3 by PRRX1 overexpression. We first per-
formed transient transfection of a vector expressing PRRX1 and a luciferase reporter construct containing part of 
the human COL6A3 promoter (COL6A3-PROM-luc) and a predicted PRRX1 binding motif (Figure S3). When 


























































































































Figure 2.  Expression of COL6A3 and PRRX1 in mature adipocytes and stromal vascular fraction (SVF). 
Adipocytes and SVF from human subcutaneous and omental whole tissue biopsies were separated by 
collagenase treatment, and gene expression was measured by qPCR using TBP as a reference gene. (A) The 
expression of PRRX1 was measured in subcutaneous adipocytes and SVF from morbidly obese people (n = 13, 
SVF n = 12), subcutaneous adipocytes in non-obese subjects (adipocyte n = 17, SVF n = 10), and omental 
adipocytes in severely obese subjects (adipocyte n = 13, SVF n = 12). Data are presented as mean ± SEM. (B) 
PRRX1 and COL6A3 mRNA were correlated in mature subcutaneous adipocytes and SVF (log2-transformed 
data, Pearson correlation). SC, subcutaneous; SVF, stromal vascular fraction. **p value < 0.01 (relative to obese 






















































































Figure 3.  PRRX1 knockdown reduces COL6A3 mRNA expression in human adipose cells. The day after 
seeding (70–80% confluence) in 12-well plates, cells were transfected with siRNA (25 nM for PRRX1 and 
10 nM for PPARG ), induced to differentiate, and left for 72 h. COL6A3 mRNA expression was measured by 
qPCR normalized to HPRT1 mRNA (SGBS) or IPO8 mRNA (hASCs). (A) Data for human SGBS preadipocytes 
presented as mean ± SD for an experiment performed in triplicate. (B) hASCs were isolated from adipose 
tissue liposuction aspirate of four people. Data are presented as mean ± SD for four independent experiments 
performed in triplicate. hASCs, primary human adipose stromal cells, siNT, non-targeting siRNA (control). *p 
value < 0.05; **p value < 0.01; ***p value < 0.001.
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we found a 2.5 to threefold increase in luciferase activity (p < 0.001) (Fig. 4A). To examine if PRRX1 also induces 
endogenous COL6A3 mRNA expression, and whether this varies with different cellular contexts, we analyzed 
mRNA in 3T3-L1 preadipocytes with stable PRRX1b overexpression, with and without adipogenic induction. 
Interestingly, while PRRX1 overexpression did not affect Col6a3 mRNA in preadipocytes before differentiation 
relative to control cells, upon adipogenic induction the PRRX1-overexpressing cells showed a threefold increase 
in endogenous Col6A3 mRNA expression (Fig. 4B).
As our transcriptome screen linked COL6A3 co-expressed genes to TGF-β/SMAD signaling (e.g., SMAD3 
and SMAD7), in line with published literature showing enhanced collagen gene expression upon TGF-β stimu-
lation in various cell  types27, we next tested if TGF-β might induce Col6a3 mRNA at least in part via Prrx1. As 
expected, TGF-β treatment increased Col6a3 mRNA in preadipocytes, and also in early adipogenic differentiation 
(Fig. 4C). PRRX1 overexpression added to the positive effect of TGF-β, although only in cells that were induced 
to differentiate (Fig. 4C). However, the TGF-β-stimulated Col6a3 expression was at least partly independent of 
changes in Prrx1 expression, since some of the cells treated with TGF-β showed reduced Prrx1 mRNA (Fig. 4C). 
These data suggest that PRRX1 did not act principally through TGF-β-dependent SMAD3 and SMAD7 tran-
scriptional activity to induce COL6A3 mRNA.
Inflammation represents another pathway in which PRRX1 might mediate increased COL6A3 expression, as 
COL6A3 has been implicated in adipose tissue  inflammation13,16, including a role in anti-inflammatory M2-type 
 macrophages14. However, it is unknown whether inflammatory factors such as TNF-α modulate COL6A3 expres-



























































































































































































































































































Figure 4.  PRRX1 transactivates the human COL6A3 promoter. (A) 3T3-L1 cells were transfected with 
expression plasmid encoding PRRX1a or PRRX1b together with a luciferase construct containing part of the 
endogenous human COL6A3 promoter with a predicted PRRX1 binding element. Data from 5 independent 
experiments performed in triplicate were combined and normalized. (B–D) A 3T3-L1 cell line stably 
overexpressing Prrx1b and a corresponding control 3T3-L1 cell line were grown to 100% confluence. Cells 
that were induced to differentiate into adipocytes were grown for an additional 2 days before treatment with 
adipogenic compounds for 2 days. The cells were treated with vehicle, TGF-β1 (1 ng/ml) or TNF-α (10 ng/
ml) for the last 24 h before lysis. Col6a3 and Prrx1b mRNA were measured by qPCR and calculated relative to 
Rplp0 mRNA. Experiments were performed in triplicates. (E) COS-1 cells were transfected with a luciferase 
reporter construct under control of either the wild-type (WT) COL6A3 promoter or the same promoter with 
a deletion in the predicted PRRX1 binding element (ΔPE) together with an overexpression plasmid encoding 
either PRRX1a or PRRX1b. An empty overexpression plasmid was used as negative control. (F) COS-1 cells 
transfected as previously with WT and ΔPE COL6A3 luciferase reporter in combination with PRRX1b, in 
addition to treatment with vehicle or TNF-α (100 ng/ml). Representative of two independent experiments. Data 
are presented as mean ± SD. Early diff., early differentiation, i.e., cells induced to differentiate into adipocytes 
for two days; Preads, preadipocytes; WT, wild-type; ΔPE, deletion of predicted PRRX1 binding element. *p 
value < 0.05; **p value < 0.01; ***p value < 0.001.
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PRRX1 and COL6A3 showed increased adipose expression after bariatric surgery in people with extreme obesity 
concomitant with markedly reduced  inflammation17, we hypothesized that TNF-α reduces COL6A3 mRNA, 
at least in part via reduced PRRX1. When treating 3T3-L1 cells with TNF-α we found 25 – 60% reduction in 
Col6a3 mRNA regardless of whether Prrx1 was overexpressed or not (Fig. 4D). In line with the stimulatory effect 
of Prrx1 overexpression on Col6a3 mRNA specifically in cells that were induced to differentiate, as opposed to 
preadipocytes (Fig. 4B,D), the decreased Col6a3 mRNA overall corresponded to decreased Prrx1 mRNA in cells 
induced to differentiate and not in preadipocytes (Fig. 4D). Of note, in the absence of Prrx1 overexpression, 
TNF-α increased Col6a3 mRNA slightly in control cells that were induced to differentiate while decreasing Prrx1 
mRNA in these cells, suggesting also Prrx1-independent regulation (Fig. 4D). Interestingly, TNF-α also markedly 
blunted the Prrx1 mRNA level in the cells that were transfected to overexpress Prrx1. While the reason for this 
effect is unclear, the decreased Prrx1 mRNA nonetheless corresponded to decreased Col6a3 mRNA (Fig. 4D).
Although our data clearly show that PRRX1 induces the transcription of COL6A3 mRNA in differentiating 
adipose cells, and that TNF-α stimulation can blunt this effect of PRRX1 at least in part by reducing PRRX1 
expression, it is not clear if PRRX1 regulates COL6A3 expression by direct binding to the COL6A3 promoter or 
indirectly via regulation of other endogenous factors. To examine this, we mutated the core of the PRRX1 bind-
ing motif in the COL6A3-PROM-luc construct, and tested the effect of PRRX1 overexpression with and without 
TNF-α in COS-1 cells, in which a PRRX1-mediated transactivation may be less dependent on the endogenous 
context of 3T3-L1 cells. Interestingly, while both Prrx1a and Prrx1b strongly increased luciferase activity as 
expected, the disrupted binding motif did not alter the PRRX1-mediated transactivation potential (Fig. 4E). How-
ever, consistent with the inhibitory effect of TNF-α on Col6a3 and Prrx1 mRNA in differentiating 3T3-L1 cells, 
TNF-α potently inhibited the stimulatory effect of PRRX1 overexpression on COL6A3 promoter activity (Fig. 4F).
Discussion
The regulation of adipose tissue function has gained considerable interest in recent years, with the realization 
that adipose tissue is an endocrine organ contributing to development of chronic diseases such as type 2 dia-
betes and  cancer1. COL6α3 is an important extracellular matrix (ECM) component in adipose tissue, showing 
altered expression in different metabolic contexts and cell types, and with a potential causal role in obesity-
related metabolic  diseases13,14,16. Adipose COL6A3 expression appears highly dynamic and context-dependent, 
as different studies have reported elevated levels upon body weight  gain13 as well as after bariatric  surgery17 and 
diet-induced weight  loss18. Importantly, previous studies have shown cell-type dependent expression of COL6A3, 
with obesity-dependent expression in  adipocytes15 but higher expression in the stromal vascular fraction (SVF) 
of adipose tissue compared to isolated  adipocytes18, expression across different adipose tissue resident mono-
cytes/macrophages (e.g., in a nondestructive, ECM-conserving29 and potentially pro-fibrotic  subtype14), and 
expression in different tumor  cells30,31. Heterogeneity in cellular phenotypes of adipose tissue in different physi-
ological contexts may therefore explain the variable results observed for COL6A3 expression in different cohorts 
and interventions of people with obesity. Transcriptional regulation of COL6A3 expression by PRRX1 helps to 
elucidate its dynamic expression, and may represent a new treatment target to modulate COL6A3 expression in 
COL6α3-dependent pathological conditions.
Our findings link PRRX1 to adipose tissue fibrosis, which associates with insulin resistance in  humans32, and 
in which COL6α3/endotrophin may play an important causal  role7,10. PRRX1 is a developmental homeobox tran-
scription factor, and has an established role in embryonic and postnatal  skeletogenesis33,34. One of few established 
target genes of PRRX1 is tenascin C (TNC)35,36, a pro-fibrotic factor involved in a Twist1-Prrx1-TNC positive 
feedback loop in fibroblast  activation37. Recent studies have revealed pro-fibrotic effects of PRRX1 in hepatic 
stellate  cells38 and lung  fibroblasts39. In hepatic stellate cells, PRRX1 was shown to transactivate the COL1A1 
 promoter40. PRRX1-mediated regulation of COL6A3 may however be of particular importance, since COL6A3 
overexpression stimulates TGF-β signaling and increases expression of other collagen  genes7.
Here we found that TGF-β increased Col6a3 mRNA expression in adipose cells, as could be expected. It 
is possible that PRRX1 at least partly increased COL6A3 expression via TGF-β, since a suppressive effect of 
PRRX1 on adipogenesis was previously found to involve TGF-β  signaling26. Together with the positive effect 
also of COL6α3 on TGF-β  signaling7, PRRX1 might be involved in a positive feedback loop between TGF-β and 
COL6A3, at least in certain cellular contexts. However, our data overall suggest that PRRX1 may induce COL6A3 
mRNA independently of TGF-β/Smad signaling, since we found that TGF-β up-regulated Col6a3 mRNA while 
decreasing or not changing Prrx1 mRNA levels in 3T3-L1 cells.
The stimulatory effect of PRRX1 overexpression on Col6a3 mRNA specifically in preadipocytes that were 
induced to differentiate, and not in cells still in the preadipocyte state, suggests that the relationship between 
PRRX1 and COL6A3 involves factors in adipocyte development. A PRRX1-COL6A3 axis may be important in 
adipogenesis and adipose tissue function related to PPARγ signaling. We previously found that PRRX1 directly 
inhibits PPARG2 expression and represses adipogenesis via a causal genetic variant that predisposes to type 2 
 diabetes25. Consistent with the inhibitory effect of PRRX1 on adipogenesis via TGF-β  signaling26, TGF-β-induced 
dedifferentiation of human adipocytes decreases PPARG expression while increasing TGFB1 and COL6A3 
 expression41,42. Here we additionally showed, during early differentiation of primary human adipose stromal 
cells, that knockdown of PRRX1 dampens the increase in COL6A3 expression seen after PPARG knockdown. 
Thus, PRRX1 may, at least in part, enhance COL6A3 expression indirectly via suppression of PPARG2 expression. 
Furthermore, knockdown of COL6A3 in immortalized primary human preadipocytes has been found to increase 
expression of adipogenic  genes16, supporting that PRRX1 inhibits adipogenesis via regulation of both PPARG2 
and COL6A3. Whether additional factors mediate the effect of altered PRRX1 levels on COL6A3 expression dur-
ing adipogenesis, and the reason why PRRX1 overexpression had no effect on Col6a3 mRNA in preadipocytes 
in our experiments, requires further investigation.
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We further gained new insight into the regulation of COL6A3 by pro-inflammatory stimuli. The down-
regulation of Col6a3 mRNA upon TNF-α treatment in 3T3-L1 cells is consistent with COL6A3 down-regulation 
in the context of inflamed adipose tissue from people with obesity, and up-regulation after bariatric surgery and 
diet-induced weight  loss17,18. Moreover, it is conceivable that reports of increased adipose COL6A3 expression 
in  obesity13,15,16 might not reflect effects of pro-inflammatory stimuli, but the activity of M2-type macrophages 
with pro-fibrotic but anti-inflammatory  properties14. Taken together, our data support that COL6A3 expression 
is positively regulated by signals involved in tissue remodeling and potentially fibrosis (e.g., TGFB1), while being 
negatively regulated by at least some pro-inflammatory stimuli.
Because several tissues express both COL6A3 and PRRX1, our discovery of PRRX1 as an upstream tran-
scriptional regulator of COL6A3 may be relevant not only for adipose tissue. COL6A3 has been implicated in 
pathogenesis of the nervous system, muscular dystrophy and isolated dystonia (a disorder of involuntary muscle 
twitching)43,44, and in different forms of cancer including of the  pancreas30,  bladder31,  colon11,  ovary45 and  breast10 
(the latter via adipose tissue). Fibrosis plays an important although complex role also in cancer, in part by char-
acterizing solid  tumors46. The adipose-COL6α3-cancer link involves the epithelial-to-mesenchymal transition 
(EMT)10, modulated by the TGF-β/Smad  pathway31 and which can be induced by  adipocytes47,48. EMT allows 
formation of mesenchymal tissues distant from the originating epithelial cells in cancer as well as in embryogen-
esis. EMT further plays a role in reversible transdifferentiation of epithelial cells into adipocytes in mammary 
 tissue49 and PPARγ2-mediated conversion of invasive breast cancer cells into fat-storing  cells50. PRRX1 is an 
established regulator of EMT in cancer  cells31,51, supporting that PRRX1 may regulate COL6A3 during EMT. 
Interestingly, the PRRX1b isoform may promote EMT and cancer cell invasion, while the PRRX1a isoform may 
promote the reverse (mesenchymal-to-epithelial transition, MET) and metastatic  outgrowth52. Taken together, 
our data suggest that PRRX1 may be a target in adipocytes and potentially other cell types to modulate COL6A3 
expression in the context of pathological conditions including cancer.
Our study has important limitations. Although the COL6A3 reporter contained a predicted consensus PRRX1 
binding site, and the PRRX1 knockdown and overexpression clearly affected endogenous COL6A3 expression, 
our data do not support that PRRX1 regulates COL6A3 mRNA by direct binding to the COL6A3 promoter. 
Rather, the regulation may be indirect by hitherto unknown endogenous factors that are regulated by PRRX1 on 
the transcriptional and/or posttranscriptional level. Despite our efforts we were unable to provide a mechanistic 
explanation for the striking and highly consistent correlations between PRRX1 and COL6A3 mRNA that we 
observed in several human cohorts. Moreover, we cannot readily explain the seemingly contradictory expression 
patterns in different cohorts reported here or in the literature, where PRRX1 and COL6A3 were downregulated in 
obesity as well as upregulated after fat loss in some cohorts, while being upregulated in insulin resistant relative 
to insulin sensitive subjects in others. Moreover, we did not assess protein expression to demonstrate that altered 
mRNA corresponds to altered protein levels, and to support that PRRX1 modulates COL6α3 function. Finally, 
although our strategy to identify transcriptional regulators of COL6A3 coupled with overexpression assays 
revealed PRRX1 as a potent regulator of COL6A3 in vitro, and these factors showed strong joint correlations with 
obesity and insulin resistance, the physiological relevance of this relationship remains to be demonstrated in vivo.
Conclusion
In conclusion, through correlation analyses based on different human cohorts, consistent co-expression pat-
terns and PRRX1 knockdown, overexpression and transactivation experiments, we have identified PRRX1 as a 
novel transcriptional regulator of COL6A3 mRNA expression in adipose cells. The PRRX1-COL6A3 axis, and 
modulators thereof yet to be discovered, may represent promising treatment targets for mitigating obesity-related 
pathogenesis, including insulin resistance and cancer. Interestingly, the present study identified TNF-α as a novel 
inhibitor of PRRX1-mediated transactivation of the COL6A3 promoter. Future studies should further dissect 
the mechanisms by which this and additional upstream pathways regulate the PRRX1-COL6A3 relationship in 
adipose and other tissues.
Methods
Ethical statement. The study was approved by the Regional Committee for Medical Research Ethics in 
Western Norway (REK Vest, approval numbers 2010/512 and 2010/3405), and the ethics committee of the 
University of Leipzig (approval number 159–12-21,052,012 and 017–12-23,012,012). Each subject gave written 
informed consent. We carried out all methods in accordance with relevant guidelines and regulations.
Subjects and biopsy for gene expression analysis. Subcutaneous (SC) and omental (OM) adipose 
tissue biopsies were obtained by surgical excision from Caucasian patients with severe obesity undergoing bari-
atric surgery in Western Norway (Førde Hospital and Voss Hospital) or in Leipzig, Germany, as previously 
 described17,24,53 (Cohorts 1–3, Table 1). Subcutaneous biopsies were also obtained from a subset of patients one 
year after the bariatric surgery and from non-obese healthy  people17 (Cohort 1). In Cohort  224, the subjects were 
dichotomized into groups of insulin sensitive obese (ISO) and insulin resistant obese (IRO) based on glucose 
infusion rate < 60 and > 70 μmol/kg/min, respectively. These patients were otherwise healthy and matched for 
age, sex, BMI and total body fat. In Cohort  353, adipocytes and the stromal vascular fraction (SVF) were isolated 
from SC adipose tissue of patients undergoing hernia repair (lean/overweight) or bariatric surgery (obese). The 
tissue was frozen immediately in liquid nitrogen and stored at –80ºC. For primary human adipose culture, lipo-
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Adipose tissue homogenization and fractionation. Frozen whole tissue (200-300 mg) was homog-
enized in a 2 ml safe-lock eppendorf tube with 1 ml Qiazol lysing buffer (Qiagen) and a 5 mm metal bead (Milli-
pore), using a TissueLyser II (Qiagen) with three repeated shakings at 25 Hz for 2 min each. To isolate adipocytes 
and SVF, 700-800 mg of adipose tissue was treated with collagenase and thermolysin (Liberase Blendzyme 3, 
Roche) for 30 min at 37ºC, followed by washing with PBS and careful centrifugation, as previously  described53. 
Cells were lysed in Qiazol within one hour ± 5 min and frozen in liquid nitrogen.
Cell lines. All cells were kept in a humidified  CO2 incubator at 37˚C with 5%  CO2 saturation. 3T3-L1 mouse 
preadipocytes were cultured in high-glucose (4.5  g/L/5  mM) DMEM with 1% penicillin and streptomycin 
(PEST), and 10% calf serum (CS) during proliferation. The cells were induced to differentiate into adipocytes 
two days post-confluence (“day 0”), by a two-day treatment with dexamethasone (0.5 mM), insulin (175 nM), 
phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) (0.5 M) and fetal bovine serum (FBS) (10%). 
Thereafter, the medium contained 10% FBS and 175 nM insulin, as well as 1 μM rosiglitazone (PPARγ agonist). 
SGBS preadipocytes were proliferated in DMEM-F12 medium containing 10% fetal calf serum (FCS) and 1% 
PEST. Differentiation was induced at 90–100% confluence by washing the cells with pre-warmed PBS repeatedly, 
and by culturing in serum-free medium (2/3 DMEM-F12 and 1/3 MCDB-131 supplemented with 1% PEST, 
10 µg/ml transferrin, 66 nM insulin, 100 nM cortisol, 1 nM T3, 0.5 nM IBMX, 25 nM dexamethasone and 2 µM 
rosiglitazone). After 3 days of incubation, the induction medium was replaced with differentiation medium (2/3 
DMEM-F12 and 1/3 MCDB-131 supplemented with 1% PEST, 10 µg/ml transferrin, 66 nM insulin, 100 nM 
cortisol and 1 nM T3). COS-1 monkey kidney cells were grown in high-glucose (4.5 g/L/5 mM) DMEM, sup-
plemented with 1% penicillin and streptomycin (PEST) and 10% fetal bovine serum (FBS).
Retroviral infection and stable overexpression. Human PRRX1b (NM_022716.4) was cloned into a 
retroviral pZOME vector carrying the puromycin resistance gene. 5 µg of constructs were transfected with plas-
mids carrying vsvg and gagpol into 293et cells using Transfectin transfection reagent (Bio-Rad). 48 h after trans-
fection, the virus particles were harvest by filtering the medium through 0.45 µm syringe filter and were stored 
at -80ºC. The day before infection, mouse 3T3-L1 cells were plated into 6-well plates. The next day the medium 
was removed and virus-containing medium was added in the presence of polybrene (4 µg/ml). Two days after 
infection the cells successfully transduced with virus were selected with puromycin (2 µg/ml). A comparable 
control cell line expressing green fluorescence protein (GFP) was also generated.
Primary human adipose culture. Human adipose stromal cells were isolated from liposuction aspirate as 
described  previously54. Tissue was digested in 50 ml NUNC tubes for about 2 h at 37ºC, with a 1:1 ratio of tissue 
and KRP buffer (0.1% BSA and ~ 55 Wunch/liter collagenase with thermolysin (Liberase Blendzyme Thermoly-
sin Medium 10X, Roche)). The tissue was then filtered through a 210 μm nylon mesh into a 125 ml cup, and cells 
were collected from underneath the floating adipocytes followed by centrifugation at 200 g for 10 min. Adipo-
cytes were washed two more times with 15 ml PBS to release cells, each time followed by collection and centrifu-
gation of the cells. Red blood cells were lysed by treating the cells for 10 min with a buffer containing 155 mM 
ammonium chloride, 5.7 mM dipotassium phosphate and 0.1 mM EDTA, followed by centrifugation at 200 g 
for 10 min. Finally, the cells were filtered through a 70 μm nylon mesh cell strainer (BD Falcon), counted using 
a Bürker chamber, and cultured in 6-well plates (~ 500,000 cells/well) with DMEM GlutaMax (GIBCO) contain-
ing 10% FCS and 1% PEST. Cells were differentiated by supplementing the medium with cortisol (100 nM/L), 
insulin (66 nM/L), transferrin (10 μg/ml), biotin (33 μM), pantothenate (17 μM/L) and T3 (1 nM/L) the day after 
seeding (day 0), changing medium every 2–3 days. For the first six days, rosiglitazone (10 μM) was also added.
Gene knock‑down by siRNA. Gene silencing by small interfering RNA (siRNA) was performed as previ-
ously  described15. On day 0, the primary human adipose cells were treated with differentiation medium and 
25 nM ON-TARGETplus human siRNA SMARTpool (Dharmacon) using HiPerFect (Qiagen) (non-targeting 
(NT) control and siRNA against PRRX1), according to the manufacturer’s protocol. Cells were collected in 
buffer RLT (Qiagen) after 72 h and stored at -80ºC until RNA extraction and PCR.
RNA extraction, cDNA synthesis and qPCR. The procedures were described  previously17. The RNe-
asy Lipid Tissue Midi Kit (whole tissue) or Mini Kit (Qiagen) was used to extract total RNA, and NanoDrop 
ND-1000 spectrophotometer (NanoDrop Technologies) was used to measure yield and quality. For whole tis-
sue, cDNA was prepared from 1 μg total RNA by the Transcriptor First Strand cDNA Synthesis Kit (Roche), 
followed by 1:10 dilution with PCR-grade water. For the cell fractions and cell culture, the SuperScript VILO 
cDNA Synthesis Kit (Invitrogen) was used according to the manufacturer’s protocol, with an input of 100 ng 
(cell fractions) and 500 ng (cell culture) total RNA per sample, followed by 1:20 dilution of the cDNA with 
PCR-grade water. Standard curves (1:5 or 1:10 dilutions) were made by synthesizing cDNA from 2.5 μg total 
RNA extracted from whole tissue or cell culture, using the SuperScript VILO kit. The LightCycler480 Probes 
Master kit and the LightCycler480 rapid thermal cycler system (Roche) were used to perform qPCR. Target and 
reference genes were amplified by specific primers and Universal ProbeLibrary (UPL) probes (Roche) shown in 
Table S1. Amplification efficiency based on the standard curves was used to calculate mRNA concentrations. 
TBP and IPO855 were chosen as reference genes based on their stable expression in adipose tissue and primary 
culture, respectively, and because they showed similar expression levels as the target genes. In Cohort 2 the refer-
ence gene was HPRT1.
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Microarray gene expression analysis. The samples were prepared and microarray analyses performed 
as described  previously17. Briefly, 300 ng of total RNA from each sample was reversely transcribed, amplified 
and Biotin-16-UTP–labeled. NanoDrop spectrophotometer and Agilent 2100 Bioanalyzer were used to meas-
ure amount (15–52 mg) and quality of the labeled cRNA. 750 ng of biotin-labeled cRNA was hybridized to 
the HumanRef-8v.3 (whole tissue) or HumanHT-12v.3 Illumina Sentrix BeadChip according to manufacturer’s 
instructions. The HumanRef-8v.3 BeadChip targets approximately 24,500 annotated RefSeq transcripts and 
covers 18,631 unique curated genes. The HumanHT-12v.3 BeadChip targets approximately 48,800 annotated 
RefSeq transcripts and covers 27,455 unique curated genes. The microarray data are MIAME compliant and 
are available in ArrayExpress (accession E-TABM-862). The HumanHT-12v.3 BeadChip was also used for the 
PRRX1 knockdown experiment in 8 primary human adipose cell cultures as described  previously25.
Transient transfection and luciferase assay. The COL6A3 promoter reporter construct (pLightSwitch_
Prom) was purchased from SwitchGear Genomics. The PRRX1a and PRRX1b plasmids were gifted by Michael J. 
Kern. Lipofectamine 2000 (Invitrogen) was used for transfecting 3T3-L1 cells with plasmid DNA, according to 
the manufacturer’s protocol. Cells were seeded the day before transfection in 24-well plates. Confluence at time 
of transfection was 70–80%. Prior to transfection, medium was removed and cells were washed with pre-heated 
(37ºC) PBS followed by addition of 400 µl serum-free medium. DNA was diluted in 100 µl Opti-MEM I Reduced 
Serum Medium (Invitrogen) and mixed by pipetting. Lipofectamine 2000 was mixed and combined with 100 µl 
Opti-MEM, before combining µl Lipofectamine and µg DNA at a 1:1 ratio.
48 h after transfection, growth medium was removed and cells were rinsed with 4ºC PBS. The plate was placed 
on ice and 80 µl lysis buffer was dispensed in each well. To ensure complete lysis the plate was placed on a shaker 
at 200-250 rpm for 30–40 min at 4ºC. The lysates were then transferred into a 96-well plate and immediately 
placed on ice, before centrifugation for 5 min at 4600 rpm. 35 µl of the supernatant was transferred to a 96-well 
plate containing luciferin and ATP substrate, before immediate measurement in a luminometer.
Mutagenesis of the COL6A3‑prom‑luc reporter. The following mutagenesis primers targeting the pre-
dicted PRRX1 binding site was designed using Agilent’s QuikChange Primer Design software (https ://www.agile 
nt.com/store /prime rDesi gnPro gram.jsp): Forward primer, 5′-TTG GTT AAC AGA AAA CCA AGG CGA TTT 
TTTGC TGG TTT TTC TATTT-3′; reverse primer, 5′-AAA TAG AAA AAC CAGCA AAAAA TCG CCT TGG TTT 
TCT GTT AAC CAA-3′. Bold-Italic letters indicate position of mutation site, flanking the two deleted base pairs 
(shown in lowercase) from the PRRX1 core binding motif (TTaaTTG). Mutagenesis was performed using the 
QuikChange II Site-Directed Mutagenesis Kit (Agilent) according to manufacturer’s instructions. Briefly, WT 
plasmid was amplified by PCR using the mutagenesis primers and a high-fidelity DNA polymerase, followed by 
DpnI digestion of methylated template DNA. The mutated plasmid was transformed in TOP10 competent E.coli 
cells (Invitrogen) and isolated using the HiSpeed Plasmid Maxi kit (Qiagen) before verification by sequencing.
TFactS analysis. TFactS analysis (https ://www.tfact s.org/TFact S-new/TFact S-v2/) was run with the fol-
lowing parameters: Catalogue selection: Sign-Less; Number of random selections: 50; P-value/E-value/Q-
value/False discovery rate (FDR) (Benjamin-Hochberg corrected) < 0.05; Random control %: 5; and Minimum 
required number of target genes: 1.
Statistical analyses. The microarray expression data (signal intensity values) were quantile  normalized56 
and log transformed (base 2). Normal distribution of COL6A3 expression across the patients was confirmed by 
Shapiro–Wilk test. Correlations were calculated by Pearson in R. Data from cell culture experiments were ana-
lyzed by Mann Whitney U or one-way ANOVA as indicated, using PASW Statistics 18 for Windows.
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